Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
Invivyd (Nasdaq: IVVD) will host a conference call on March 5, 2026 at 8:30 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) will host a conference call on March 5, 2026 at 8:30 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a corporate update.
Interested parties can access a live webcast and analysts can join the Q&A via designated links; a recording will be posted to the company investor relations website shortly after the event.
Details
News Market Reaction – IVVD
On Mar 3, the first trading day after this news, IVVD closed 5.81% below the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Preliminary Q4 2025 PEMGARDA revenue
- $17.2M
- Preliminary net product revenue, Q4 2025
- PEMGARDA YoY growth
- 25%
- Q4 2025 net product revenue growth year-over-year
- PEMGARDA QoQ growth
- 31%
- Q4 2025 net product revenue growth quarter-over-quarter
- Cash and equivalents
- $226.7M
- Expected ending balance after >$200M raised in 2H 2025
- DECLARATION enrollment
- 1,770 participants
- Expected total enrollment for Phase 3 VYD2311 trial
- Net tangible book value
- $169.1M
- Pro forma as of June 30, 2025 from S-3 filing
- Book value per share
- $0.58
- Pro forma net tangible book value per share, June 30, 2025
- Earnings call time
- 8:30 a.m. ET, March 5, 2026
- Fourth quarter and full-year 2025 results conference call
Previous Conferences,earnings Reports
-
Announced Nov 6, 2025 Q3 2025 results and corporate update call.
-
Set May 15, 2025 call for Q1 2025 results and updates.
-
Planned Nov 14, 2024 call on Q3 2024 results and business updates.
-
Announced Aug 14, 2024 Q2 2024 results and highlights call.
-
Outlined May 9, 2024 call for Q1 2024 results and highlights.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update.
Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company’s investor relations website shortly after the event.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.